key: cord-1031523-knl4as8f authors: So, Jennifer Y; O'Hara, Nathan N; Kenaa, Blaine; Williams, John G; deBorja, Christopher L; Slejko, Julia F; Zafari, Zafar; Sokolow, Michael; Zimand, Paul; Deming, Meagan; Marx, Jason; Pollak, Andrew N; Reed, Robert M title: Decline in COPD Admissions During the COVID-19 Pandemic Associated with Lower Burden of Community Respiratory Viral Infections date: 2021-06-12 journal: Am J Med DOI: 10.1016/j.amjmed.2021.05.008 sha: 46ddc4c4a223ad0f8af44a09ef5fa0f9c86ea3f5 doc_id: 1031523 cord_uid: knl4as8f Background: The COVID-19 pandemic has led to widespread implementation of public health measures, such as stay-at-home orders, social distancing, and masking mandates. In addition to decreasing spread of SARS-CoV2, these measures also impact the transmission of seasonal viral pathogens, which are common triggers of COPD exacerbations. Whether reduced viral prevalence mediates reduction in COPD exacerbation rates is unknown. Methods: We performed retrospective analysis of data from a large, multicenter healthcare system to assess admission trends associated with community viral prevalence and with initiation of COVID-19 pandemic control measures. We applied difference-in-differences (DiD) analysis to compare season-matched weekly frequency of hospital admissions for COPD before and after implementation of public health measures for COVID-19. Community viral prevalence was estimated using regional Center for Disease Control and Prevention test positivity data and correlated to COPD admissions. Results: Data involving 4,422 COPD admissions demonstrated a season-matched 53% decline in COPD admissions during COVID-19 pandemic, which correlated to community viral burden (r=0.73; 95% CI: 0.67 to 0.78) and represented a 36% greater decline over admission frequencies observed in other medical conditions less affected by respiratory viral infections (IRR, 0.64; 95% CI, 0.57 to 0.71, p<0.001). The post-COVID-19 decline in COPD admissions was most pronounced in patients with fewer comorbidities and without recurrent admissions. Conclusion: The implementation of public health measures during the COVID-19 pandemic was associated with decreased COPD admissions. These changes are plausibly explained by reduced prevalence of seasonal respiratory viruses. -COPD admissions declined by 53% during COVID-19 pandemic -COPD admissions decline was 36% greater than admissions for other common diagnosis -Patients with fewer comorbidities and single admissions had greater admission decline -Public health measures during pandemic led to decline in respiratory virus prevalence -Decline in respiratory viruses is associated with drop in COPD admissions Background: The COVID-19 pandemic has led to widespread implementation of public health measures, such as stay-at-home orders, social distancing, and masking mandates. In addition to decreasing spread of SARS-CoV2, these measures also impact the transmission of seasonal viral pathogens, which are common triggers of COPD exacerbations. Whether reduced viral prevalence mediates reduction in COPD exacerbation rates is unknown. Methods: We performed retrospective analysis of data from a large, multicenter healthcare system to assess admission trends associated with community viral prevalence and with initiation of COVID-19 pandemic control measures. We applied difference-in-differences (DiD) analysis to compare season-matched weekly frequency of hospital admissions for COPD before and after implementation of public health measures for COVID-19. Community viral prevalence was estimated using regional Center for Disease Control and Prevention test positivity data and correlated to COPD admissions. Prior to the COVID-19 pandemic, chronic obstructive pulmonary disease (COPD) was the fourthleading cause of death worldwide and a common cause of hospital admissions in the United States. 1-4 COPD exacerbations cause a staggering burden of morbidity, mortality, and cost to the health care system. [5] [6] [7] The recent COVID-19 pandemic has led to a significant interruption in health care delivery, with reduced admissions for COPD and other non-COVID illnesses. [8] [9] [10] [11] [12] [13] This is due to a variety of factors, including avoidance of crowded hospitals due to fear of contracting SARS-CoV2 (the virus responsible for COVID-19), reallocation of hospital resources to treat rising number of COVID-19 patients, and utilization of telemedicine to manage chronic diseases at home. There is compelling evidence indicating that public health measures (such as stay at home orders, social distancing, and masking mandates with strict limitations on large gatherings to curb the spread of are also effective at decreasing the transmission of seasonal viral pathogens. 14, 15 It is plausible that measures taken to reduce the spread of SARS-CoV2 have also resulted in reductions in COPD exacerbations, due in large part to reduced burden of non-SARS-CoV2 community virus transmission. Respiratory viral infections are the most commonly identified trigger for COPD exacerbations. They are implicated in approximately 50% of cases, and result in a disease course that tends to be more severe and longer in duration. 16, 17, 18 We aimed to determine whether public health measures related to the COVID-19 pandemic were associated with reduced seasonal viral infections and COPD-related hospital admissions. Using data from a large, multicenter healthcare system, we hypothesized that the public health measures related to the COVID-19 pandemic decreased hospital admissions for COPD exacerbations. We conducted a difference-in-differences analysis of retrospective data to compare weekly hospital admissions for COPD pre-versus post-COVID-19 public health measures. Stay-at-home mandate and masking mandate were instituted in the state of Maryland on March 30 th ,2020 and April 18 th , 2020, respectively. April 1 st , 2020 was selected as the start of post-COVID-19 period. A difference-in-differences model estimates the average effect among an exposure group while controlling for factors unrelated to the exposure of interest that would affect both exposed and unexposed groups. In this case, a key difference between the groups is the association to respiratory viral infections as triggers for destabilization and subsequent Table 1a -s). We selected a control group of primary diagnoses that would account for a similar reservation among patients to seek hospital care due to a fear of COVID-19 transmission. The control group included all admissions with a primary diagnosis of myocardial infarction, diabetes mellitus, or congestive heart failure, and were identified using ICD-10-CM codes (Online supplement, Table 1b-s). The control group diagnoses were also selected for informative epidemiologic aspects. Both congestive heart failure and myocardial infarction admission rates experience seasonal variability and are associated with trends in viral infections, although less robustly than observed in COPD. [19] [20] [21] [22] As such, selection of these diagnoses was an intentionally conservative approach. Diabetes, on the other hand, demonstrates little seasonality, although it warrants emphasis that all analyses were seasonally controlled. Only the patients with the above ICD-10-CM codes were included in the study. The analyses were restricted to only include data from April 1 through September 30 in 2018 through 2020 to ensure a seasonal match. The period prior to implementation of public health measures included data from 2018 and 2019, and the period after implementation included data from 2020. The study was approved by the University of Maryland institutional review board (HP-00093452). The primary outcome was weekly hospital admissions. Secondary outcomes included weekly counts of in-hospital mortality, severe exacerbations (identified as requiring intensive care unit admission), and hospital length of stay. Additionally, we calculated community viral percent positivity to assess the correlation between viral trends and COPD admissions. Data on respiratory virus incidence was provided by the Centers for Disease Control and Prevention's Patient characteristics were extracted from the electronic health records to assess for any imbalance between time periods or exposure groups. We also used ICD-10-CM codes to generate Charlson Comorbidity Index scores, and diagnoses of morbid obesity, tobacco use, alcohol-related disorders, substance-related disorders, and social challenges (Online supplement, Table 1s ,c-d). The primary analysis of the change in weekly hospital admissions applied a negative binomial model, adjusting for an observed imbalance between periods in patient age and a weekly time trend. We included a dummy variable for the admitting hospital as a random effect in the model to account for variation in public health measure adherence and socioeconomic compositions among the catchment areas. We used Pearson's correlation coefficients to evaluate the association between community viral percent positivity data with admissions for COPD, congestive heart failure, diabetes mellitus, and myocardial infarction. The in-hospital mortality and severe exacerbation models were fit using negative binomial regression. We used a quantile regression model to evaluate the effect of the COVID-19-related public health measures on the median hospital length of stay days among COPD patients. In all models, we adjusted for patient age and accounted for the hospital as a random effect. We performed two subgroup analyses to assess heterogeneity of effect based on comorbidities and recurrent admissions. The comorbidities were identified at the time of admission, and reported using the Charlson Comorbidity Index (CCI) which was stratified between patients with a CCI <3 and patients with a CCI >3 (Online supplement 1s-c). 24 Patients were classified as having recurrent admissions if they had more than one admission for the same primary diagnosis during the study period. The subgroup term was interacted with the comparison groups and exposure for a difference-in-difference-in-differences model. With this approach, we accounted for the subgroup covariate as an interaction term to the difference-indifferences equation. This model ascertained if the difference-in-differences estimate changed between subgroups. We performed two sensitivity analyses. In the first analysis, we added patients who had a primary admission diagnosis of COVID-19 and a secondary diagnosis of COPD (Online supplement 1s-e) to the COPD group. The intention of this analyses was to determine if the decline in COPD admissions was due to related COVID-19 diagnosis taking precedence in the diagnosis. In the second analysis, we rebuilt three versions of our primary difference-indifferences model, one model for each control group's primary admission diagnosis -congestive heart failure, diabetes mellitus, or myocardial infarction. The purpose of this sensitivity analyses was to evaluate if our estimates were robust across the various control groups. Difference-in-differences estimates for the negative binomial models are reported as an incidence rate ratio with 95% confidence intervals. The difference-in-differences estimates for the quantile regression model is reported as the change in median days of hospital stay with 95% confidence intervals. Confidence intervals were calculated using bootstrap methods. The analyses were performed with R Version 4.0.0 (Vienna, Austria). For the primary analysis, we considered a two-tailed p < 0.05 as statistically significant. We did not adjust for multiple testing, and all secondary outcomes should be considered exploratory. We did not impute for missing data. Table 1 . Notably, the average age of COPD patients admitted during the post-COVID-19 period was older (62.7 ± 16.5 years) compared to pre-COVID-19 period (55.3 ± 24.4 years). There were no significant differences in gender, race, or distribution of Charlson Comorbidity Index scores. The mean age of all patients with COPD admission was 57 ± 23 years, and more than half were female (n=2,499, 57%). The majority of these patients had three or fewer comorbidities (n=3683, 83%). The post-COVID crude weekly COPD admissions decreased by 53% compared to the pre-COVID-19 seasonally-comparable period (31.5 vs. 67.4 admissions/week respectively). Compared to declines observed in other medical conditions, weekly COPD admissions demonstrated a 36% greater decline (incidence rate ratio (IRR), 0.64; 95% CI, 0.57 to 0.71, p<0.001) (Table 2, Figure 1 ). To ensure that the results were not attributable to concomitant SARS-CoV2 infection, a sensitivity analysis was performed including admissions for primary diagnosis of COVID-19 with a secondary diagnosis of COPD included in the COPD group. The findings remained significant even with this conservative approach (Online supplement, Table 3s ). The results were also consistent within subsets of the control group admitted for congestive heart failure (IRR, 0.66; 95% CI, 0.59 to 0.75), diabetes mellitus (IRR, 0.57; 95% CI, 0.51 to 0.65), and myocardial infarction (IRR, 0.69; 95% CI, 0.60 to 0.77) (Online supplement Table 4s ). In addition, there was an apparent temporal correlation between weekly COPD admissions and community viral percent positivity (r, 0.73; 95% CI: 0.67 to 0.78) (Figure 2 ). There were no significant differences of in-hospital mortality (0. (Table 2) . Similarly, there were no significant differences in median hospital length of stay for COPD admissions. The difference in COPD admissions pre-vs. post-COVID-19 period was most pronounced for patients with three or fewer comorbidities, assessed using CCI (IRR, 0.60; 95% CI, 0. 49 to 0.75) ( Figure 3 , Online supplement Table 5s ). The reduction in COPD admissions associated with the post COVID-19 period was greater for patients without recurrent admissions than for patients with recurrent admissions (IRR, 0.66; 95% CI, 0.53 to 0.81) (Online supplement Table 5s ). This study documents a substantial decline in weekly COPD admissions occurring during the COVID-19 pandemic. The reduction is greater in COPD admissions than that observed in other medical conditions less strongly associated with respiratory viral infections. This observation can be plausibly explained by reductions in community respiratory viral infections consequent to measures taken to control SARS-CoV2 transmission. Our study includes data from a large, multihospital health system which allows us to minimize potential bias due to hospital resource allocation, such as admission limitation of non-COVID-19 patients or transfer of such patients to accommodate COVID-19 patients. All hospitals were located in a single state and, therefore, we assume more homogeneity in the observed public health measures. We included each of the 13 hospitals in the system as a random effect in our models to account for possible differences in the sociodemographics of the hospital catchments that may influence the study findings. In addition, our data included weekly admission trends dating back to 2018, allowing for a granular evaluation of changes over time. We also assessed other possible causes of the decrease in COPD admissions, including a subgroup analysis comparing patients with varying degrees of comorbidities and frequency of exacerbations, and by correlating our findings with respiratory viral trends. The difference-indifferences models was seasonally-matched and included other diagnostic conditions to account for hospital avoidance due to fear of COVID-19 transmission. There have been prior publications that described declines in hospital admissions during the pandemic. One large study described reductions in emergency room presentations ranging from 41.5% to 63.5%, with greater reductions observed in areas more heavily affected by the pandemic. 13 Birkmeyer et al. examined admission frequencies across a large nationwide medical group and found substantial declines to a low of 42.8% below normal. In that study, COPD admissions dropped more than any other diagnostic group to a nadir reduction of 68.6%, and despite admissions for some other conditions returning to pre-pandemic levels, COPD admissions remained 40.1% lower than baseline. 12 A variety of mechanisms have been proposed to explain declines in medical admissions for various major non-COVID-19 conditions, but the apparently greater decline in COPD admissions has been inadequately explained. The decrease in admissions for all causes relate to a global reduction in hospital and emergency department visits, likely due to patients' fear of contracting SARS-CoV2 virus in these settings. 13, 25, 26 There has also been a shift towards telemedicine, and more patients are treating symptoms at home than in the hospital, both of which may contribute to lowering overall hospitalization. 27, 28 However, there are additional factors that may play a role specific to the COPD population. These include improvements in air quality during the pandemic, potential increased adherence to COPD controller medications and changes in rates of smoking during the pandemic. 29 30 31 Overall, the degree of reduction from each of these measures is likely small and fails to explain such a large, immediate reduction in COPD admissions. As viral infections account for 40-50% of COPD exacerbations, the most likely explanation for the large decrease in COPD admissions is the reduction of respiratory virus prevalence in the population. 4, 17 Exacerbations caused by a virus also tend to be more severe and longer-lasting than non-viral exacerbations (median 13 days compared to 6 days, respectively). 17 Our data also show that the reduction in COPD admissions was greatest in those with fewer comorbidities. COPD exacerbations occurring during the COVID-19 pandemic may have been associated with a patient's underlying poor health condition at baseline. In addition, a change in engagement with the health care system during the pandemic, such as avoidance of crowded emergency department visits, may have led to a shift toward outpatient management of COPD exacerbations, especially in those with fewer comorbidities and less severe disease. Those patients with fewer comorbidities may have been able to manage exacerbations at home better than those with multiple comorbidities and baseline poor physiologic reserve. Often, these patients tend to be younger and likely explains the shift in mean age of COPD patients in the post-COVID-19 group. Older patients with more comorbidities and more severe COPD experience more frequent exacerbations, regardless of respiratory viral infections, and may not experience the decrease seen in those with fewer comorbidities. A few limitations of our study deserve mention. Our analysis is based on hospital admission data, creating a possibility for coding variability among providers and possible misdiagnosis. However, the use of ICD codes in health services research is widely accepted, and we have employed ICD codes consistent with prior studies. [35] [36] [37] Our data did not permit granular evaluation of whether COPD exacerbations complicated by COVID could influence ICD codes chosen, but we performed a sensitivity analysis in which the case definition of COPD exacerbation was modified to include admissions in which COVID was listed as a primary diagnosis with COPD listed as a comorbidity. Results remained significant, suggesting there was not a major issue related to misclassification bias. Another limitation involves the inclusion of control diagnoses that manifest a degree of seasonality related to community respiratory viral infections. This was an intentionally conservative approach that may underestimate the true magnitude of the reduction in COPD exacerbations attributable to respiratory viral infections. Finally, the lack of statistical significance observed in the secondary endpoints could reflect power limitations rather than a true lack of association. There is a significant decrease in weekly COPD admissions during the COVID-19 pandemic, likely due to a decrease in respiratory virus prevalence from public health measures being taken during the pandemic. There may be opportunity to judiciously apply control measures outside of pandemic conditions to reduce the burden of disease imparted by community respiratory viral infections. National Health Interview Survey: Tables of Summary Health Statistics 3. Agency for Healthcare Research and Quality. Most common Diagnoses for Inpatient Stays. HCUP Fast Stats-Most Common Diagnoses for Inpatient Stays Respiratory viral infection in exacerbations of COPD Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic Reduction in Hospital Admissions for COPD Exacerbation During the Covid-19 Pandemic. Open Respiratory Archives Collateral Effect of Covid-19 on Stroke Evaluation in the United States Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy Pandemic On Hospital Admissions In The United States. Health Aff (Millwood) Trends in Emergency Department Visits and Hospital Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic in the US Decreased Influenza Activity During the COVID-19 Pandemic -United States Public health measures during COVID-19 pandemic reduced hospital admissions for community respiratory viral infections Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction Effects of ambient temperature on the incidence of myocardial infarction Heart failure in a cold climate Seasonal variation in heart failure-related morbidity and mortality Annual rates of admission and seasonal variations in hospitalizations for heart failure Prevention CfDCa. The National Respiratory and Enteric Virus Surveillance System (NREVSS) Validation of a combined comorbidity index Delayed access or provision of care in Italy resulting from fear of COVID-19 The Untold Toll -The Pandemic's Effects on Patients without Covid-19 Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals Virtually Perfect? Telemedicine for Covid-19 Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic Will the tobacco industry ultimately triumph in the midst of COVID-19 pandemic?: A call for nurses' action in tobacco control COPD-related morbidity and mortality after smoking cessation: status of the evidence The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations Unintended Consequence: Influenza plunges with public health response to COVID-19 in Singapore Age-Related Differences in the Rate, Timing, and Diagnosis of 30-Day Readmissions in Hospitalized Adults With Asthma Exacerbation Trends in 30-day readmission rates after COPD hospitalization Comorbidity and Mortality in COPD-Related Hospitalizations in the United States The grey shaded areas denote data that were not included in the season-matched analysis. The pandemic time period was associated with a 53% decline in COPD admissions (from 67.4 to 31.5 admissions/week) which represented a 36% greater decline than that observed in other medical indications evaluated